GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boule Diagnostics AB (STU:8BD) » Definitions » Cyclically Adjusted Revenue per Share

Boule Diagnostics AB (STU:8BD) Cyclically Adjusted Revenue per Share : €1.65 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Boule Diagnostics AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Boule Diagnostics AB's adjusted revenue per share for the three months ended in Mar. 2025 was €0.270. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.65 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Boule Diagnostics AB's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Boule Diagnostics AB was 10.10% per year. The lowest was 7.30% per year. And the median was 9.00% per year.

As of today (2025-05-07), Boule Diagnostics AB's current stock price is €0.698. Boule Diagnostics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €1.65. Boule Diagnostics AB's Cyclically Adjusted PS Ratio of today is 0.42.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boule Diagnostics AB was 4.06. The lowest was 0.37. And the median was 1.64.


Boule Diagnostics AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Boule Diagnostics AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boule Diagnostics AB Cyclically Adjusted Revenue per Share Chart

Boule Diagnostics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.45 1.56 1.57 1.53

Boule Diagnostics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 1.57 1.56 1.53 1.65

Competitive Comparison of Boule Diagnostics AB's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Boule Diagnostics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Cyclically Adjusted PS Ratio falls into.


;
;

Boule Diagnostics AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boule Diagnostics AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.27/132.8245*132.8245
=0.270

Current CPI (Mar. 2025) = 132.8245.

Boule Diagnostics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.317 99.995 0.421
201509 0.355 100.228 0.470
201512 0.349 100.276 0.462
201603 0.340 100.751 0.448
201606 0.406 101.019 0.534
201609 0.418 101.138 0.549
201612 0.379 102.022 0.493
201703 0.407 102.022 0.530
201706 0.413 102.752 0.534
201709 0.422 103.279 0.543
201712 0.382 103.793 0.489
201803 0.358 103.962 0.457
201806 0.384 104.875 0.486
201809 0.388 105.679 0.488
201812 0.345 105.912 0.433
201903 0.416 105.886 0.522
201906 0.411 106.742 0.511
201909 0.445 107.214 0.551
201912 0.455 107.766 0.561
202003 0.396 106.563 0.494
202006 0.314 107.498 0.388
202009 0.335 107.635 0.413
202012 0.301 108.296 0.369
202103 0.467 108.360 0.572
202106 0.387 108.928 0.472
202109 0.395 110.338 0.475
202112 0.553 112.486 0.653
202203 0.465 114.825 0.538
202206 0.458 118.384 0.514
202209 0.436 122.296 0.474
202212 0.420 126.365 0.441
202303 0.323 127.042 0.338
202306 0.323 129.407 0.332
202309 0.308 130.224 0.314
202312 0.347 131.912 0.349
202403 0.333 132.205 0.335
202406 0.303 132.716 0.303
202409 0.296 132.304 0.297
202412 0.325 132.987 0.325
202503 0.270 132.825 0.270

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Boule Diagnostics AB  (STU:8BD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Boule Diagnostics AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.698/1.65
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boule Diagnostics AB was 4.06. The lowest was 0.37. And the median was 1.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Boule Diagnostics AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Boule Diagnostics AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Boule Diagnostics AB Business Description

Traded in Other Exchanges
Address
Domnarvsgatan 4, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The firm focuses on the decentralized market segment. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. Through its subsidiaries, the Group operates in Sweden, USA, and China.

Boule Diagnostics AB Headlines

No Headlines